| Literature DB >> 25282263 |
Silvia Dei1, Marcella Coronnello2, Elisa Floriddia3, Gianluca Bartolucci3, Cristina Bellucci3, Luca Guandalini3, Dina Manetti3, Maria Novella Romanelli3, Milena Salerno4, Ivan Bello4, Enrico Mini2, Elisabetta Teodori3.
Abstract
As a continuation of our research on potent and efficacious P-gp-dependent multidrug resistance (MDR) reversers, several new N,N-bis(alkanol)amine aryl esters were designed and synthesized, varying the aromatic moieties or the length of the methylenic chain. The new compounds were tested on doxorubicin-resistant erythroleukemia K562 cells (K562/DOX) in the pirarubicin uptake assay, where most of the new compounds were shown to be active. In particular the asymmetrical compounds, characterized by two linkers of different length, generally showed fairly high activities as MDR reversers. Some selected compounds (isomers 15-17) were further studied by evaluating their doxorubicin cytotoxicity enhancement (reversal fold, RF) on the K562/DOX cell line. The results of both pharmacological assays indicate that compounds 16 (GDE6) and 17 (GDE19) could be interesting leads for the development of new P-gp dependent MDR modulators.Entities:
Keywords: Chemosensitizers; Doxorubicin-resistant erythroleukemia K562 cells (K562/DOX); MDR reversers; N,N-bis(alkanol)amine aryl esters; P-gp inhibitors; Pirarubicin uptake
Mesh:
Substances:
Year: 2014 PMID: 25282263 DOI: 10.1016/j.ejmech.2014.09.084
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514